tert-butyl (S)-(1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)carbamate

Catalog No. :
ACJVXQ864
CAS No. :
1429181-55-4
Molecular Formula :
C19H28F2N2O2
Molecular Weight :
354.44

IUPAC Name:tert-butyl (S)-(1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)carbamate

tert-butyl (S)-(1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl (S)-(1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)carbamate
IUPAC Nametert-butyl (S)-(1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)carbamate
Molecular FormulaC19H28F2N2O2
Molecular Weight354.44
SMILESO=C(OC(C)(C)C)N[C@H](C1=CC=C(CN2CCC(F)(F)CC2)C=C1)C
InChI KeySSUCLIDFRKIXTP-AWEZNQCLSA-N
Synonym(S)-tert-butyl (1-(4-((4,4-difluoropiperidin-1-yl)methyl)phenyl)ethyl)carbamate;Carbamic acid, N-[(1S)-1-[4-[(4,4-difluoro-1-piperidinyl)methyl]phenyl]ethyl]-, 1,1-dimethylethyl ester
CAS No.1429181-55-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACJVXQ864 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFGCD759 route compound structure diagram
    ACFGCD759144230-52-4 In Stock
  4. Then
  5. ACJVXQ864 route product structure diagram
    ACJVXQ8641429181-55-4
Inquiry

2. ACJVXQ864 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFGCD759 route compound structure diagram
    ACFGCD759144230-52-4 In Stock
  4. Then
  5. ACJVXQ864 route product structure diagram
    ACJVXQ8641429181-55-4
Inquiry

Comments (0)